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Abstract
Background:  MUC5AC is a secreted mucin aberrantly expressed by colorectal polyps and
carcinoma. It has been hypothesized that aberrant expression of MUC5AC in colorectal carcinoma
tissues increased the overall survival of patients with colorectal carcinoma. The present study
investigates the incidence of naturally occurring MUC5AC antibodies in the sera of normal
individuals, patients with colonic polyps and patients with advanced colorectal carcinoma. A second
aim was to determine the relationship of MUC5AC antibody with the prognosis of colorectal
carcinoma.
Methods:  Free circulating MUC5AC antibodies were measured using an enzyme-linked
immunosorbent assay with a synthetic peptide corresponding to an 8 aa. segment of MUC5AC
tandem repeat region. Immunohistochemical analysis was completed to demonstrate MUC5AC
expression in the polyp specimens.
Results: MUC5AC antibodies were detected in 6 of 22 (27.3%) healthy subjects, 9 of 20 (45%)
polyp patients, 18 of 30 (60%) patients with colorectal cancer. The presence of circulating free
MUC5AC antibody levels was significantly correlated with expression of MUC5AC in polyp
sections. Serum MUC5AC antibody positivity was higher in patients with colon located tumors,
advanced stage and poorly differentiated tumors were found negatively affecting patient survival in
our study. MUC5AC antibody positivity was higher in patients with poor prognostic parameters.
Disease free survival and overall survival were shorter in this group of patients. In the multivariate
analysis MUC5AC antibody positivity didn't find an independent prognostic factor on prognosis.
Conclusion:  Decreased survival in colorectal carcinoma patients with MUC5AC antibody
positivity may be due to a decrease in the MUC5AC expression in tumor tissues of surviving
carcinoma patients.
Background
Mucins are high molecular weight glycoproteins with O-
linked oligosaccharides attached to serine or threonine
residues of the apomucin protein backbone [1]. To date,
19 genes coding for apomucin have been identified [2-5].
Mucins are expressed with a cell and tissue-specific pattern
in normal tissues [6,7]. There are two structurally and
functionally distinct classes of mucins; secreted gel-form-
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ing mucins and transmembrane mucins. Secreted gel-
forming mucins include the products of the MUC2,
MUC5AC, MUC5B and MUC6 genes on chromosome
11p15.5 [8-10]. Each has a central region with a variable
number of tandem repeat (VNRT), but there is a little sim-
ilarity. MUC5AC was cloned from tracheobronchial [11]
and stomach [12] cDNA libraries. Tandem repeat units
have eight amino acid residues [12].
MUC5AC expression is found on apical epithelial cells of
the mucus glands of gastric antrum and body, tracheo-
bronchial epithelium, superficial epithelium of the gall-
bladder and endocervix epithelium [7,13-22]. MUC5AC
is found in fetal [23,24] and precancerous [25] colonic
mucosa but <20% of normal colon tissue [7,25-28]. De
novo expression was shown in >55% of colonic polyps.
MUC5AC is highly expressed in adenoma. Levels decrease
with increasing degree of dysplasia in polyps
[25,26,29,30]. Less than 30% of colorectal carcinomas
expressed MUC5AC [23,30]. However, in another study,
there was de novo expression of MUC5AC in 23/36 color-
ectal carcinomas [31]. In our previous study, we reported
34.1% of colorectal carcinomas expressed MUC5AC [32].
We emphasized that MUC5AC expression decreases with
increased malignancy pathology and MUC5AC negative
tumors had a more malignant potential, as shown by a
more aggressive behavior. These patients had a signifi-
cantly shorter survival in our study. We suggested that the
absence of MUC5AC expression in colorectal carcinomas
might be a negative prognostic factor.
Humoral and cellular immune responses to other mucin
core proteins have been described in cancer patients.
Tumor reactive cytotoxic T-lymphocytes specific for MUC-
Table 1: Characteristics of colorectal carcinoma patients and prognostic effect on DFS and OVS.
Number (%) DFS (months) P value OVS (months) P value
Age
60≤ 17 56.7 10.5 0.0184 34 0.216
>60 13 43.3 18.9 48.4
Sex
Female 12 40 18.2 0.221 42.2 0.782
Male 18 60 11.5 39
Tumor location
Colon 24 80 10.1 0.0272 34.8 0.0111
Rectum 6 20 30.3 62
Dukes Stage
A-
B 8 26.7 25.7 0.0002 50.2 0.0076
C 11 36.7 17.8 48.4
D 11 36.7 2.18 24.9
Histologic type
Adeno Ca 27 90 14.92 0.455 42.55 0.0243
Mucinous Ca 1 3.3 10.0 13.0
Adenosquamous Ca 1 3.3 13.0 27.0
Adenocarcinoid Ca 1 3.3 0.0 20.0
Differentiation
Well differentiated 6 20 8.3 0.0407 46.3 0.002
Moderately differentiated 19 63.3 18.6 43.9
Poorly differentiated 4 13.3 5.5 21.7
Colloid (mucinous) 1 3.3 0.0 9
Metastatic Lymph Node
Absent 8 26.7 25.7 0.0398 50.25 0.259
Present 22 73.3 10.0 36.68
Preoperative Metastasis
Absent 19 64.3 21.1 0.000 49 0.0018
Present 11 36.6 2.18 24.91
Serum MUC5AC Ab level
Negative 12 40 19.91 0.153 50.0 0.052
Positive 18 60 10.38 33.83
DFS = Disease Free Survival
OVS = Overall SurvivalBMC Gastroenterology 2006, 6:4 http://www.biomedcentral.com/1471-230X/6/4
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1 core peptides have been described in breast [33], pancre-
atic [34] and ovarian [35] cancer patients. Circulating
immune complexes [36,37] and free anti-mucin antibody
[38-40] against the MUC 1 tandem repeat also have been
identified in patients with benign and malignant tumors.
The specific aims of the present study are to investigate the
incidence of humoral immune response against MUC5AC
core protein in healthy individuals, patients with colorec-
tal polyps and colorectal carcinoma, and the possible clin-
ical importance of this antigen for the diagnosis and
prognosis of colorectal carcinoma.
Methods
Serum samples were obtained from 22 healthy donors,
from 20 patients with colonic polyps, and from 30 color-
ectal carcinoma patients with recurrent or progressive dis-
ease treated in the University of Pittsburgh Medical
Center. Serum samples were collected, and stored at – 70
degrees until analyzed. Tissue sample from polyp patients
were obtained from the Pathology Department. Colorec-
tal carcinoma tissues were not available for this study.
Healthy subjects
Mean age of healthy donors was 47.6 years (range 30–80
years) and half of them were male.
Polyp patients
Mean age of polyp patients was 58.6 years (range 34–74).
Forty-five percent of them (n = 9) were female and 55% of
them (n = 11) were male. A total of 43 polyps were ana-
lyzed; 21% of them were hyperplastic, 67.5% were tubu-
lar adenomatous, 9.2% were tubulovillous and 2.3% were
villous type. Polyp size was classified as < 1 cm, 1–2 cm, >
2 cm. Seventy five percent of polyps were smaller than 1
cm, 5.6% were between 1–2 cm and 1.4% of polyps were
bigger than 2 cm size. Only 4.2% of polyps showed dys-
plastic changes.
The patients were divided into three groups in order to
show relationship between antibody level and having of
polyps at past or present time. Group I (55%) patients
were newly diagnosed, group II (30%); had a present and
past history of colonic polyps, group III (15%) had a past
history of polyps only.
Colorectal cancer patients
Median age was 59 years (range 22–71). Clinicopatho-
logic parameters of these patients were given in Table 1;
Tumors were staged according to the modified Dukes'
classification proposed by Astler and Coller [41]. Histo-
logic typing of tumors was performed using the World
Health Organization classification [42]. The duration of
follow-up ranged from 7–92 months (median 39
months). All of the patients died during the follow-up
period.
Table 2: MUC5AC serum antibody levels in healthy controls, in polyp and malignant colorectal carcinoma patients. Serum mean 
MUC5AC antibody levels were higher in colorectal carcinoma patients when compared with polyp patients (p = 0.049) and a control 
population (p = 0.011).
Healthy controls (n = 22) Polyp group (n = 20) Carcinoma group (n = 30)
* No. > 0,225 6 (27.3%) 9 (45%) 18 (69%)
Mean 0.219 OD 0.268 OD 0.322 OD
Median Range (min-max) 0.195 OD (0.13–0.41) 0.207 OD (0.06–0.95) 0.277 OD (0.12–0.96)
* Number of patients that have higher MUC5AC antibody level than 0.225 OD.
OD = Optical density
The ROC curve-comparing controls with colorectal carci- noma and polyp patients shows 0.618 of validity Figure 1
The ROC curve-comparing controls with colorectal carci-
noma and polyp patients shows 0.618 of validity. ROC = 
receiving operating characterizing. The cut off level was 
taken as OD 0.225. At this value maximal sensitivity 54% and 
specificity 73% were attained.
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Synthesis of tandem repeat peptides
MUC5AC peptide sequence TTSTTSAP was prepared by
the Peptide Synthesis Facility at the University of Pitts-
burgh.
Elisa for detection of mucin-specific antibodies
Circulating free antibodies to MUC5AC were measured
with an Enzyme-linked immunoassay (ELISA). The pep-
tide was dissolved in Phosphate Buffered Saline (PBS) at
concentration 5 µg/ml. The solution (100 µl) was dis-
pensed into 96-well plates and incubated overnight at
4°C. The plate was washed 3 times with PBS and the
remaining protein-binding sites blocked by a 1 hour incu-
bation with 100 µl of 2.5% BSA (Bovine serum albumin)
(Sigma, St Louis, MO) in PBS. The control plate has no
MUC5AC peptide. Serial plasma dilutions of 1:20-1:160
were prepared in 2.5% BSA. After 1-hour incubation with
50 µl of primary antibody, plates were washed 5 times
with 0.1% tween 20 in PBS. The plate was then incubated
for 1 h with 50 µl of the secondary antibody consisting of
goat antihuman polyvalent (IgM, IgA, IgG) antibody
(Sigma Chemical Co. St. Louis, MO) diluted 1: 1000 with
2.5% BSA. The plate was washed 5 times and 100 µl sub-
strate was added. Sigma 104 Phosphatase Substrate was
Table 3: Serum MUC5AC antibody levels (OD unit) and MUC5AC expression in pathology specimens of polyp patients.
Group I (n = 11) Group II (n = 6) and Group III (n = 3)
Serum Antibody 
Level
Expression of 
MUC5AC in polyp 
specimens
Serum Antibody 
level
Expression of MUC5AC in polyp 
specimens
New Previous
Antibody positive 0.948 (+)* 0.225 (+)(+) (-)(+)(-)(-)
0.312 (+) (-)(+)
0.616 (+)(+)
0.317 (-) 0.246 (-) (+)
0.275 (+)(-)
0.227 (+) 0.53 (-)
Antibody negative 0.165 (-)(-) 0.055 (-)(+) (+)
0.143 (-)(+) 0.163 (+)(-) (+)
0.219 (-) 0.195 (-) (-)
0.146 (-) 0.151 (+) (-)(-)(-)(-)(+)
0.127 (-)
0.14 (+)(+)
0.128 (-)
*: Each parenthesis represents the histology of one polyp specimens and MUC5AC expression.
(-): No MUC5AC staining at polyp specimens
(+): MUC5AC staining at polyp specimens
HP: Hyperplastic polyp
TA: Tubuler adenoma
TV: Tubulovillous adenoma
V: Villous adenoma
OD = Optical density
Incidence of circulating MUC5AC antibody in sera of healthy  subjects, polyps, and colorectal carcinoma Figure 2
Incidence of circulating MUC5AC antibody in sera of healthy 
subjects, polyps, and colorectal carcinoma. As an arbitrary 
cut-off level 0,225 OD units was chosen. OD: Optical den-
sity.BMC Gastroenterology 2006, 6:4 http://www.biomedcentral.com/1471-230X/6/4
Page 5 of 9
(page number not for citation purposes)
used at 3 mg/ml in 0.05 M NaCO3, 0.5 mM MgCl2. The
reaction was stopped after 1 hour of incubation in the
dark with 50 µl of 0.5 M NaOH and the Optical Density
(OD) read at 405 nm. Each result from the MUC5AC +
plate is subtracted from the MUC5AC – control plate,
results are a mean of three replicates.
The isotype determination of antimucin antibody was car-
ried out as described above using IgG or IgM specific sec-
ondary antibodies (Sigma, St. Louis, MO).
Immunohistochemistry
Monoclonal anti-human gastric mucin antibody (clone
45M1; Sigma, St. Louis, MO) was used to determine
MUC5AC expression in polyp tissues. This antibody rec-
ognized the mucin epitope "g", located in the peptide core
of MUC5AC [29]. Endocervical was used as a positive con-
trol [32]. Anti-MUC5AC antibody was diluted 1:200 with
BSA. Sections were stained by immunoperoxidase tech-
nique using the Vectastain Elite ABC kit protocol (Vector
Laboratories Inc., Burlingame, CA). Antibody expression
higher than 10% of the tumor recorded as positive expres-
sion in immunohistochemical study [32].
Statistical analysis
Statistical analysis was performed using the program SPSS
advanced statistics 10.0 software package (SSPS Inc, Chi-
cago, Illinois, USA). Differences of MUC5AC serum anti-
body levels between groups were analyzed with Mann
Whitney U test. Differences between the MUC5AC anti-
body positivity within groups were evaluated with Chi-
square test, relationships between clinicopathologic
parameters and MUC5AC antibody positivity were evalu-
ated with Chi square or, when the sample size was small,
a Fischer's exact test. The probability of parameters on Dis-
ease Free Survival (DFS) and Overall Survival (OVS) was
analyzed using Kaplan-Meier method. Multivariate analy-
sis of parameters on DFS and OVS was performed using
Cox regression models.
Results
In order to determine the positive cut off level of serum
MUC5AC Ab, a ROC (receiving operating characterizing)
curve was constructed between the normal and pathologic
(polyps and colorectal carcinoma patients) groups. The
cut off level was taken as OD 0.225. At this value maximal
sensitivity 54% and specificity 73% were attained (Figure
1). We found that >70% of healthy controls expressed
antibody levels <OD 0.225. Mean and median serum
MUC5AC antibody results at a 1:20 antibody dilution is
shown in Table 2. Total mean antibody levels were higher
in colorectal carcinoma patients when compared to the
control population (p = 0.011) and the polyp population
(p = 0.049). No difference was found between polyp
group and control group (p > 0.05).
Figure 2 shows the number of MUC5AC antibody positive
individuals. MUC5AC antibody positive individuals were
significantly higher in colorectal carcinoma 60% than in
healthy controls 27.3% (p = 0.019). The number of posi-
tive individuals in the polyp group 45% was not signifi-
cantly different from the healthy controls (p = 0.231).
The polyps that have size between 1 and 2 cm had higher
incidence of serum MUC5AC Ab positivity than polyps
smaller than 1 cm size (75%–40%) (p > 0.05). MUC5AC
antibody positivity was seen in 66.6% of hyperplastic pol-
yps, 40% of tubular adenoma, and 67% of tubulovillous
adenoma. Incidence of MUC5AC Ab positivity was higher
in patients with tubulovillous adenoma than patients
with tubular adenoma (66.7%–38.5%; p > 0.05). Proba-
bly, because the number of polyps in each different polyp
group were small, the differences are not statistically sig-
nificant. Patients with villous adenoma didn't have
MUC5AC Ab in sera and MUC5AC expression in polyp
specimen. Presence of dysplasia didn't cause any differ-
ence in MUC5AC Ab positivity in sera and MUC5AC
expression in polyp specimens. This might be due to a low
number of polyps with dysplasia.
Of all polyp patients, 54% of group I, 33.3% of group II
and 33.3% of group III had high levels of antibody. The
differences between groups were not significant. We com-
pared the presence of MUC5AC antibody with the expres-
sion of MUC5AC in the resected polyp tissue. In group I
patients, 83.3% of the patients with high serum MUC5AC
antibody also had MUC5AC expression in the pathology
specimens (Table 3). Among antibody negative patients
in group I, 80% had negative MUC5AC expression in their
polyp specimen. Within Group II and III, MUC5AC
expression in the pathology specimens did not correlate
with serum MUC5AC antibody levels. Having MUC5AC
expression at polyp specimens cause antibody formation
against MUC5AC antigen at patients sera in the same time
period. Having MUC5AC positive polyps at past history
did not cause permanent MUC5AC antibody positivity. In
polyp patients IgM antibodies were predominantly found.
Relationship of MUC5AC antibody positivity with 
clinicopathologic parameters of colorectal carcinoma 
patients
Although these were not statistically significant, serum
MUC5AC antibody positivity was higher in patients with
poor prognostic parameters, these include tumors located
in the colon (66.7% of MUC5AC Ab positivity in colon
located tumors and 33.3% in rectum located tumors), at
advanced stage (50% in Dukes B, 45.5% in Dukes C,
72.8% MUC5AC Ab positivity in Dukes D tumors), pres-
ence of preoperative metastases (72.8% vs 52.6%), and
with poor and mucinous differentiated tumors (50% pos-
itivity in well differentiated tumors, 50% in moderately,BMC Gastroenterology 2006, 6:4 http://www.biomedcentral.com/1471-230X/6/4
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100% in poor differentiated tumors and 100% MUC5AC
Ab positivity in mucinous differentiated tumors) (Table 4;
p > 0.05). These parameters also negatively affect the OVS
in our study groups (Table 1). IgG antibodies were pre-
dominantly found in colon carcinoma patients.
Disease free survival (dfs)
Average disease free survival was 14.2 months. Mean DFS
was 19.91 for MUC5AC antibody negative patients and
10.38 months for MUC5AC antibody positive patients.
This difference was not statistically significant (p = 0.122).
Overall survival (ovs)
Average of overall survival of the patients was 40.3
months (7–92 months). Mean OVS was 50 months for
patients with MUC5AC antibody negative patients and
33.83 months for MUC5AC antibody positive patients (p
= 0.052; Figure 3). MUC5AC antibody level did not signif-
icantly affect on prognosis in multivariate analyses.
Discussion
In the present study we have demonstrated the presence of
antibodies to MUC5AC epitopes in sera of healthy indi-
viduals, patients with polyps and colorectal carcinoma.
MUC5AC is normally expressed in respiratory, reproduc-
tive and gastric mucosa. Qualitative and quantitative
alterations in the expression of the MUC5AC have been
reported in both preneoplastic and neoplastic lesions. The
expression decreases following neoplastic transformation
in the stomach [15-18], gallbladder [19,20] and endocer-
vix [21,22], de novo expression is seen in ovarian cancer
Table 4: Serum MU5AC positivity in each clinicopathologic parameters
MUC5AC Ab negative MUC5AC Ab positive
N (%) N (%)
Age
≤60 (5) 29.4 (12) 70.6
>60 (7) 53.8 (6) 46.2
(p = 0.176)
Sex
Female (8) 66.7 (4) 33.3
Male (4) 22.2 (14) 77.8
(p = 0.015)
Tumor Location
Colon (8) 33.3 (16) 66.7
Rectum (4) 66.7 (2) 33.3
(p = 0.116)
Duke's Stage
B (4) 50.0 (4) 50.0
C (6) 54.5 (5) 45.5
D (27) 31.3 (8) 72.7
(p = 0.25)
Histologic type
Adeno Ca (12) 44.4 (15) 55.6
Mucinous Ca - - (1) 100
Adenosquamous Ca - - (1) 100
Adenocarcinoid Ca - - (1) 100
(p = 0.528)
Differentiation
Well (3) 50.0 (3) 50.0
Moderate (9) 47.4 (10) 52.6
Poor - - (4) 100
Mucinous - - (1) 100
(p = 0.260)
Metastatic Lymph Node
Absent (3) 37.5 (5) 62.5
Present (9) 40.9 (3) 59.1
(p = 0.866)
Preoperative Metastasis
Absent (9) 47.4 (10) 52.6
Present (27) 31.3 (8) 72.7
(p = 0.219)BMC Gastroenterology 2006, 6:4 http://www.biomedcentral.com/1471-230X/6/4
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[43], breast cancer [44], preneoplastic and neoplastic
lesion of pancreas [45-48] and intrahepatic bile duct
[45,49].
Genetic events that stimulate MUC5AC expression in the
colon occur early in carcinogenesis. Studies have shown
very low levels of MUC5AC in normal colonic mucosa
[28]. MUC5AC expression increases in polyps of interme-
diate stage and size or with villous histology or low-grade
dysplasia. It was stated that with an increasing degree of
dysplasia expression decreases [25,26]. In an immunohis-
tochemical study using non-tandem repeat antibodies,
there was de novo expression of MUC5AC in 23/36 carci-
nomas. More MUC5AC protein was detected in well and
moderately differentiated tumors than in poorly differen-
tiated tumors (31).
In the present study, MUC5AC expression was found in
46.5% of polyp specimens. Serum MUC5AC antibody
correlated well with the presence of MUC5AC expression
in polyp specimens. Past history of polyps did not seem to
confer permanent immunity. Only 33% of patients with
history of polyps had high level of MUC5AC antibody lev-
els. MUC5AC antibody positivity was seen in 66.6% of
hyperplastic polyps, 40% of tubular adenoma, and 67%
of tubulovillous adenoma. Incidence of MUC5AC Ab pos-
itivity was higher in patients with tubulovillous adenoma
than patients with tubular adenoma (66.7%–38.5%; p >
0.05). In probability, because of the small numbers of
polyps in each different polyp group, the differences were
not statistically significant. Antibodies in polyp patients
were primarily of the IgM isotype.
In our previous study [32], we demonstrated that colorec-
tal carcinoma patients with MUC5AC negative tumors
had poor clinicopathological parameters and showed
worse survival than patients having MUC5AC positive
tumors. The presence of MUC5AC antibodies in the
serum of colorectal carcinoma patients showed no signif-
icant correlation with various clinicopathological param-
eters in our results. With tumor progression,
immunosupression may occur during the course of dis-
ease. These patients may be unable to respond to
MUC5AC on the tumor, thus antibody levels may not cor-
relate with clinicopathologic parameters. We were unable
to determine the expression of MUC5AC in the tumor tis-
sues because we could not access these tissues in the retro-
spective study. Without measurements of tumor
associated MUC5AC antigen and circulating immune
complex concentrations, it is not possible to determine
whether the decrease in circulating antibody is due to the
sequestering of antibody by the tumor or in the form of
immune complexes or to decreased antibody production
due to immunosuppression. However, the different anti-
body levels in our study still could be prognostic indica-
tors. In this retrospective study, we have found a decreased
in DFS and OVS in patients who have high free circulating
MUC5AC antibody.
IgG antibodies were predominantly found in colorectal
carcinoma patients. A significant IgG antibody response
to MUC5AC in colorectal carcinoma patients may be
indicative of a CD4 helper T cell response. Patients were
faced firstly with MUC5AC Ag at polyp tissues. MUC5AC
antigen in polyps caused IgM type antibody formation. In
adenoma-carcinoma sequence, with facing to persistent
MUC5AC antigenity caused IgG type immune response.
There is no data regarding the cellular immune responses
to MUC5AC. Building on our previous results, we could
suggest that the serum MUC5AC antibody level would be
low in colorectal carcinoma patients with favorable out-
come for these tumors would be expressing more
MUC5AC. Free antibody could form immune complexes
with cells or circulating antigen, thereby removing it from
the serum. In more malignant tumors with low MUC5AC,
measurable circulating free antibody levels would be high.
The technique of ELISA to detecting serum MUC5AC anti-
body level could be improved by examining two issues.
Firstly, we used only one repeat sequence of 8 aminoacid.
The sensitivity of ELISA may be increased by using at least
2 repeats of tandem repeat unit. It might provide epitopes
for better recognition of antibodies present in sera. The
other issue is that there are different MUC5AC glycoforms
Survival curve of the colorectal tumor patients with  MUC5AC antibody positive and MUC5AC antibody negative  determined by the Kaplan Meier method Figure 3
Survival curve of the colorectal tumor patients with 
MUC5AC antibody positive and MUC5AC antibody negative 
determined by the Kaplan Meier method. MUC5AC antibody 
positive patients showed significantly worse survival than 
those with MUC5AC antibody negative patients (p = 0.052). 
Cum Survival = Probability of cumulative survival. OVS = 
Overall survival.
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that encoded with MUC5AC gene. Also MUC5AC glyco-
peptides can be efficiently produced by chemoenzymatic
synthesis (17). Several monoclonal antibodies were also
recognized epitopes encoded by the MUC5AC gene (29).
Further studies can be done by using different MUC5AC
glycopeptides and monoclonal antibodies in order to bet-
ter discriminate the most accurate patients to examine.
Conclusion
In conclusion, this is an initial study on a limited number
of patients showing some promising data. It shows natu-
rally occurring antibodies reacting with the core protein of
the MUC5AC mucin in the serum of healthy people,
polyp and colorectal carcinoma patients. In polyp
patients, the presence of serum MUC5AC antibody corre-
lates with the expression of MUC5AC antigen in the
patients polyp specimen. In colorectal carcinoma patients
we demonstrate the presence of serum MUC5AC antibod-
ies is associated with decreased survival. This may corre-
late with our previous finding that decreased survival is
associated with low expresion of MUC5AC.
Circulating MUC5AC antigen and antibody-antigen
immune complexes could be measured in order to test the
sequestering of antibody. Further studies in a large
number of patients may show the presence of serum
MUC5AC antibody is a prognostic factor for colorectal
carcinoma, and determine if a immune response has any
functional antitumor activity and/or whether stimulation
of this response by vaccination strategies will lead to clin-
ically beneficial antitumor activity. The ultimate goal
would be to induce antitumor activity at the early carcino-
genesis or at the polyp stage to prevent the carcinoma.
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